From Our 2013 Archives
FDA OKs New Hydrocodone Painkiller
Latest Chronic Pain News
The new drug -- Zohydro ER (hydrocodone bitartrate extended-release capsules) -- was approved for patients with pain severe enough to require daily, 24-hour, long-term treatment and for which other pain treatments are inadequate.
It is not approved for as-needed pain relief.
The approval is based on safety findings from studies of more than 1,100 people with chronic pain and efficacy findings from a study of more than 500 patients with chronic low back pain. That study found that those who took the drug had significant improvements in pain compared to those who took a placebo, according to the FDA.
Zohydro ER is classed as a "Schedule II" medication, which means it will be subject to the same type of strict controls as other narcotics with the highest potential for abuse, including OxyContin, methadone, fentanyl, Adderall and Ritalin.
One physician who is experienced with pain medication believes the new drug should not have been approved, however.
"This product was specifically turned down by the FDA Advisory Committee due to the risks of misuse, abuse, overdose and death, particularly given the limited data supporting the benefits of this medication for chronic pain," said Dr. Lewis Nelson, a professor in the department of emergency medicine in the division of medical toxicology at NYU School of Medicine, in New York City.
He said that, "other similar products already exist that come in safer formulations. The new [risk-limiting] requirements will have an undefined impact on the safety of this very dangerous medication. This is not necessarily an improvement in existing therapy and will likely result in increased use and increased cost to patients with chronic pain."
Under the new approval, the drug maker will have to conduct ongoing studies of Zohydro ER to assess the known serious risks of misuse, abuse, increased sensitivity to pain, addiction, overdose and death associated with long-term use beyond 12 weeks. These studies will also be required for other extended-release/long-acting (ER/LA) painkillers, the FDA said.
The agency also noted that Zohydro ER will be part of the ER/LA Opioid Analgesics Risk Evaluation and Mitigation Strategy. That program requires drug companies to offer health care professionals educational programs on how to safely prescribe extended-release/long-acting opioid painkillers. The companies must also provide medication guides and patient counseling documents with information on the safe use, storage and disposal of extended-release/long-acting opioids.
On Thursday, the FDA proposed tighter controls on prescriptions for painkillers that contain hydrocodone. The changes would cut in half the number of refills that patients can get before seeing their doctor to get a new prescription. Patients would also have to take their prescription to a pharmacy to have it filled, rather than have their doctor call it in.
The FDA added that it will ask in mid-December that all prescription drugs containing hydrocodone be reclassified as "Schedule II" medications.
The agency said the changes are meant to reduce the epidemic levels of prescription drug abuse in the United States.
-- Robert Preidt
SOURCE: Lewis Nelson, M.D., professor, department of emergency medicine in the division of medical toxicology, NYU School of Medicine, New York City; U.S. Food and Drug Administration, news release, Oct. 25, 2013
- Allergic Skin Disorders
- Bacterial Skin Diseases
- Bites and Infestations
- Diseases of Pigment
- Fungal Skin Diseases
- Medical Anatomy and Illustrations
- Noncancerous, Precancerous & Cancerous Tumors
- Oral Health Conditions
- Papules, Scales, Plaques and Eruptions
- Scalp, Hair and Nails
- Sexually Transmitted Diseases (STDs)
- Vascular, Lymphatic and Systemic Conditions
- Viral Skin Diseases
- Additional Skin Conditions